Has established a special licensing agreement with Ramot at Tel Aviv University Ltd.

Champions Biotechnology obtains global rights to Tel Aviv University’s TAR-1 compound Champions Biotechnology, Inc. , an oncology medication development organization with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established a special licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University’s wholly possessed technology transfer company hur-man-anvander-cialis.html . The licensing agreement encompasses the commercialization and advancement of TAR-1, a single-chain antibody fragment in preclinical advancement that may possess an edge in treating cancer individuals due to the high specificity and affinity to binding mutant p53 protein.


Ishani consults for the Chronic Disease Research Group. Haifeng Guo; Thomas Arneson, MD; Lih-Wen Mau, PhD; Suying Li, PhD; and Stephan Dunning have employment with the Chronic Disease Study Group. David Gilbertson, PhD and Allan Collins, MD have received consulting charges from Amgen.. Modification to Medicare reimbursement plan might pose dangers to black kidney individuals A transformation in Medicare reimbursement policy could make it more difficult for African Us citizens with kidney disease to gain access to dialysis providers, suggests a study in an upcoming issue of the Journal of the American Society of Nephrology . The change in payment policy may disadvantage a considerable group of dialysis patients, responses Areef Ishani, MD .